Navigation Links
Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
Date:1/15/2008

SAN MATEO, Calif., Jan. 15 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported preliminary results of a second Phase IIb clinical trial of A-002, for the treatment of cardiovascular disease. In this second study, administration of once-daily A-002 lowered both sPLA2 and LDL-C levels confirming the positive effects of A-002 treatment seen in the twice-daily PLASMA study (Phospholipase Levels And Serological Markers of Atherosclerosis) announced in October 2007.

The second trial was a multi-center, randomized, double-blind, placebo- controlled trial that enrolled approximately 140 patients with stable coronary heart disease in the U.S. Subjects were randomized to receive one of two different daily doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint was reduction in secretory phospholipase A2 (sPLA2) levels. Secondary endpoints included a number of lipid and inflammatory biomarkers. The Company plans to present data from the Phase IIb trial at scientific meetings in 2008.

"We are extremely pleased to validate the findings of our first PLASMA study, with once-a-day dosing of A-002 which further enhances our development and commercial flexibility," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "We look forward to meeting with the FDA to discuss our plans for Phase III. We expect the registration program will target patients with coronary heart disease with associated hyperlipidemia and inflammation who are currently not achieving adequate cholesterol control with diet, exercise, and existing statin therapies such as Lipitor(R)."

Data from the first PLASMA trial demonstrated that in addition to lowering sPLA2, treatment with A-002 resulted in significant reductions in blood levels of total cholesterol, Non-High Density Lipoprotein Cholesterol (non HDL-C), and Low Dens
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... November 2014 Clementia ... gegeben, dass die Europäische Arzneimittel-Agentur (European ... als Orphan-Medizinprodukt an Palovarotene vergeben hat, ... Behandlung von Fibrodysplasia ossificans progressiva (FOP). ... genetische Krankheit, die von schmerzhaften, wiederkehrenden ...
(Date:11/21/2014)... , Nov. 21, 2014 ... European Medicines Agency (EMA) has granted Orphan ... lead product candidate, for the treatment of ... rare, severely disabling genetic disease characterized by ... (flare-ups) and new abnormal bone formation. This ...
(Date:11/21/2014)... Ohio and MELVILLE, N.Y. ... CAH ), one of the world,s largest ... HSIC ), the world,s largest provider of ... health and medical practitioners, today announced that the companies ... one of the most comprehensive service and product offerings ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
(Date:11/21/2014)... (PRWEB) November 21, 2014 Center for ... workshops titled “Massachusetts Insurance Funding for Autism Workshops” to ... navigate their way through the insurance coverage process. ... Massachusetts law and the most effective ways to access ... Dec. 4 from 6-8:00 p.m. at 331 Montvale Ave., ...
(Date:11/21/2014)... Mo (PRWEB) November 21, 2014 ... the Get With The Guidelines®–Heart Failure Gold-Plus Quality ... outlined by the American Heart Association/American College of ... heart failure patients. , Get With The Guidelines–Heart ... hospital teams provide the most up-to-date, research-based guidelines ...
(Date:11/21/2014)... Columbus, OH (PRWEB) November 21, 2014 ... their contract with the Ohio Chapter, American Academy of ... and provide safe sleep education to parents and caregivers ... and continues through June 30, 2015, provides $75,000 to ... , “The Ohio Children’s Trust Fund is excited to ...
(Date:11/21/2014)... 2014 Big Bud Farms announced today ... of Innovations with Ed Begley Jr., airing via Discovery ... , Big Bud Farms, growers of legal medical marijuana, ... utilization of medical marijuana. , This segment of Innovations ... variety of products for medicating. Viewers will learn about ...
(Date:11/21/2014)... The typical Thanksgiving dinner table is crowded ... gravy and a myriad of mouthwatering desserts. Who would ... year to begin losing weight? Listen closely. With a ... to losing unhealthy, embarrassing and uncomfortable fat while still ... insight to Diet Doc’s calorie loading holiday diet ...
Breaking Medicine News(10 mins):Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 2Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 3Health News:Big Bud Farms to be Featured in Upcoming Episode of Innovations with Ed Begley Jr. 2Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 2Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 3Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 4
... NEW YORK, February 22 NexGen Biofuels Ltd.,(NASDAQ: ... its symbol to,"NXGN"., The company has changed its ... HCTL to NXGN, to more clearly reflect its new ... and to produce such,fuel through the acquisition of existing ...
... MELVILLE, N.Y., Feb. 22 /PRNewswire-FirstCall/-- Gentiva Health,Services, Inc. ... of,comprehensive home health and related services, announced today ... to 3:55 p.m. ET, Monday, March 3, 2008,at ... in,Orlando, Florida., The event will be available ...
... Calif., Feb. 22 Sutter Health is creating ... care and specialist,physicians committed to providing patients with ... The Sutter Medical Network,will have a presence in ... from Sonoma County to the Central Valley and ...
... Inclinix, Inc., an enrollment,contract research organization (CRO) and provider ... its,executive management team:, -- Steven M. Agnoff, has ... President of Marketing and Product Management. In this ... to the corporate marketing and product ...
... Physicians Coalition,for Injectable Safety has issued a statement ... after reports of serious complications,following treatment with Botox ... Botox(R) injections for cosmetic indications or,who are considering ... recent reports of adverse events, but must put ...
... IT, Sales and Large-Project Management ... Provider,s Partner Channel, BLOOMFIELD HILLS, Mich., Feb. ... (EHR) software and practice,management solutions provider serving healthcare ... has joined,gloStream,s executive management team as chief channel ...
Cached Medicine News:Health News:Gentiva(R) Health Services to Present March 3rd at Raymond James' 29th Annual Institutional Investors Conference in Orlando 2Health News:Gentiva(R) Health Services to Present March 3rd at Raymond James' 29th Annual Institutional Investors Conference in Orlando 3Health News:Sutter Health Launches Northern California Physician Network 2Health News:Sutter Health Launches Northern California Physician Network 3Health News:Inclinix, Inc. Announces Executive Management Team Changes 2Health News:Clarity for Consumers on Botox Complication and Death Reports 2Health News:Clarity for Consumers on Botox Complication and Death Reports 3Health News:Clarity for Consumers on Botox Complication and Death Reports 4Health News:Nationally Recognized Information Technology Veteran and Entrepreneur John Bamberger Joins gloStream, Inc. as Chief Channel Officer 2
Disposable tracheostomy care tray....
Disposable tracheostomy care tray....
... Solution For Your Tracheostomy Care Needs, ... features the latest components for efficient and ... task. Designed by clinicians, these latex-free trays ... patient and caregiver. All of our trays ...
... and alternate care facilities with a ... which offer the finest in nursing ... the guidance of experienced nursing personnel, ... what is required for efficient and ...
Medicine Products: